US Stock MarketDetailed Quotes

SAB Biotherapeutics (SABS)

Watchlist
  • 3.470
  • -0.270-7.22%
Close May 1 16:00 ET
  • 3.500
  • +0.030+0.86%
Post 20:01 ET
243.86MMarket Cap-4.39P/E (TTM)

SAB Biotherapeutics (SABS) Revenue Breakdown Overview

By Business/Source

Currency:USD
2024/FY
Stock NameRevenueRatio
Development of a human anti-thymocyte globulin focused on preventing or delaying the progression of1.32M100.00%

By Country/Region

Currency:USD
2024/FY
Stock NameRevenueRatio
United States1.32M100.00%
Market Insights
China Concept Stocks
View More
Middle East conflict spreads to the stock market! How should investors respond?
On May 1, the more than two-month-long military conflict involving the US, Israel, and Iran will reach a legal milestone, potentially increa Show More